Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 3, 2015, Pages 275-284

  Bowler, Russell P ^a   Jacobson, Sean ^a   Cruickshank, Charmion ^a   Hughes, Grant J ^b   Siska, Charlotte ^b   Ory, Daniel S ^c,d   Petrache, Irina ^e,f   Schaffer, Jean E ^c,d   Reisdorph, Nichole ^a   Kechris, Katerina ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ceramides; Emphysema; Genomics; Metabolomics; Sphingomyelins

Indexed keywords

CERAMIDE DERIVATIVE; CERAMIDE TRIHEXOSIDE; DIHEXOSYLCERAMIDE; GANGLIOSIDE; SPHINGOLIPID; SPHINGOMYELIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLYCOSPHINGOLIPID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EMPHYSEMA; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SMOKING; SPHINGOLIPID METABOLISM; ADVERSE EFFECTS; BLOOD; GENE EXPRESSION REGULATION; METABOLISM; MONONUCLEAR CELL; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

BIOMARKERS; GENE EXPRESSION REGULATION; GLYCOSPHINGOLIPIDS; HUMANS; LEUKOCYTES, MONONUCLEAR; MASS SPECTROMETRY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SMOKING; SPHINGOMYELINS; TRIHEXOSYLCERAMIDES;

EID: 84922308684     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201410-1771OC     Document Type: Article

References (38)

1. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep 2013;61:1-117.
2. Friedlander AL, Lynch D, Dyar LA, Bowler RP. Phenotypes of chronic obstructive pulmonary disease. COPD 2007;4:355-384.
3. Petrache I, Petrusca DN, Bowler RP, Kamocki K. Involvement of ceramide in cell death responses in the pulmonary circulation. Proc Am Thorac Soc 2011;8:492-496.
4. Bahr TM, Hughes GJ, Armstrong M, Reisdorph R, Coldren CD, Edwards MG, Schnell C, Kedl R, LaFlamme DJ, Reisdorph N, et al. Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2013;49:316-323.
5. Ahmed FS, Jiang XC, Schwartz JE, Hoffman EA, Yeboah J, Shea S, Burkart KM, Barr RG. Plasma sphingomyelin and longitudinal change in percent emphysema on CT. The MESA lung study. Biomarkers 2014;19:207-213.
6. Telenga ED, Hoffmann RF, Ruben t'Kindt, Hoonhorst SJ, Willemse BW, van Oosterhout AJ, Heijink IH, van den Berge M, Jorge L, Sandra P, et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. Am J Respir Crit Care Med 2014;190:155-164.
7. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139-150.
8. Uhlig S, Gulbins E. Sphingolipids in the lungs. Am J Respir Crit Care Med 2008;178:1100-1114.
9. Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis 2011;5:325-344.
10. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005;11:491-498.
11. Scarpa MC, Baraldo S, Marian E, Turato G, Calabrese F, Saetta M, Maestrelli P. Ceramide expression and cell homeostasis in chronic obstructive pulmonary disease. Respiration 2013;85:342-349.
12. Petrusca DN, Van Demark M, Gu Y, Justice MJ, Rogozea A, Hubbard WC, Petrache I. Smoking exposure induces human lung endothelial cell adaptation to apoptotic stress. Am J Respir Cell Mol Biol 2014;50:513-525.
13. Petrusca DN, Gu Y, Adamowicz JJ, Rush NI, Hubbard WC, Smith PA, Berdyshev EV, Birukov KG, Lee CH, Tuder RM, et al. Sphingolipid-mediated inhibition of apoptotic cell clearance by alveolar macrophages. J Biol Chem 2010;285:40322-40332.
14. Cordts F, Pitson S, Tabeling C, Gibbins I, Moffat DF, Jersmann H, Hodge S, Haberberger RV. Expression profile of the sphingosine kinase signalling system in the lung of patients with chronic obstructive pulmonary disease. Life Sci 2011;89:806-811.
15. Diab KJ, Adamowicz JJ, Kamocki K, Rush NI, Garrison J, Gu Y, Schweitzer KS, Skobeleva A, Rajashekhar G, Hubbard WC, et al. Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema. Am J Respir Crit Care Med 2010;181:344-352.
16. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010;7:32-43.
17. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001;46:798-825.
18. Carolan BJ, Kim YI, Williams AA, Kechris K, Lutz S, Reisdorph N, Bowler RP. The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:561-566.
19. Yang Y, Cruickshank C, Armstrong M, Mahaffey S, Reisdorph R, Reisdorph N. New sample preparation approach for mass spectrometry-based profiling of plasma results in improved coverage of metabolome. J Chromatogr A 2013;1300:217-226.
20. Stouffer SA. The American soldier. Princeton: Princeton University Press; 1949.
21. Liptak, T. On the combination of independent tests. Magyar Tudomanyos Akademia Matematikai Kutato Intezetenek Kozlemenyei 1958;3:171-179.
22. Taniguchi M, Okazaki T. The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration-from cell and animal models to human disorders. Biochim Biophys Acta 2014;1841:692-703.
23. Hojjati MR, Jiang XC. Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. J Lipid Res 2006;47:673-676.
24. Levy M, Khan E, Careaga M, Goldkorn T. Neutral sphingomyelinase 2 is activated by cigarette smoke to augment ceramide-induced apoptosis in lung cell death. Am J Physiol Lung Cell Mol Physiol 2009;297:L125-L133.
25. Medler TR, Petrusca DN, Lee PJ, Hubbard WC, Berdyshev EV, Skirball J, Kamocki K, Schuchman E, Tuder RM, Petrache I. Apoptotic sphingolipid signaling by ceramides in lung endothelial cells. Am J Respir Cell Mol Biol 2008;38:639-646.
26. Petrache I, Petrusca DN. The involvement of sphingolipids in chronic obstructive pulmonary diseases. In: Gulbins E, Petrache I, editors. Sphingolipids in disease. Handbook of experimental pharmacology. Vol. 216. Heidelberg, Germany: Springer-Verlag GmbH; 2013. pp. 247-264.
27. Inokuchi J. Physiopathological function of hematoside (GM3 ganglioside). Proc Jpn Acad, Ser B, Phys Biol Sci 2011;87:179-198.
28. Kuroki Y, Gasa S, Ogasawara Y, Shiratori M, Makita A, Akino T. Binding specificity of lung surfactant protein SP-D for glucosylceramide. Biochem Biophys Res Commun 1992;187:963-969.
29. Kitatani K, Sheldon K, Rajagopalan V, Anelli V, Jenkins RW, Sun Y, Grabowski GA, Obeid LM, Hannun YA. Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation. J Biol Chem 2009;284:12972-12978.
30. Wang RY, Abe JT, Cohen AH, Wilcox WR. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage. J Inherit Metab Dis 2008;31:S369-S374.
31. Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF. Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol Genet Metab 2013;108:241-248.
32. Young N, Van Brocklyn JR. Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp Cell Res 2007;313:1615-1627.
33. Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao YQ, Keith RL, Boé DM, Morimoto K, Bowler RP, Day BJ, et al. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am J Respir Crit Care Med 2009;179:1011-1021.
34. Schweitzer KS, Hatoum H, Brown MB, Gupta M, Justice MJ, Beteck B, Van Demark M, Gu Y, Presson RG Jr, Hubbard WC, et al. Mechanisms of lung endothelial barrier disruption induced by cigarette smoke: role of oxidative stress and ceramides. Am J Physiol Lung Cell Mol Physiol 2011;301:L836-L846.
35. Hu W, Xu R, Sun W, Szulc ZM, Bielawski J, Obeid LM, Mao C. Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its down-regulation inhibits both cell proliferation and apoptosis. J Biol Chem 2010;285:7964-7976.
36. Michel S, Busato F, Genuneit J, Pekkanen J, Dalphin JC, Riedler J, Mazaleyrat N, Weber J, Karvonen AM, Hirvonen MR, et al.; PASTURE study group. Farm exposure and time trends in early childhood may influence DNA methylation in genes related to asthma and allergy. Allergy 2013;68:355-364.
37. Kihara A, Igarashi Y. FVT-1 is a mammalian 3-ketodihydrosphingosine reductase with an active site that faces the cytosolic side of the endoplasmic reticulum membrane. J Biol Chem 2004;279:49243-49250.
38. Kudo N, Kumagai K, Tomishige N, Yamaji T, Wakatsuki S, Nishijima M, Hanada K, Kato R. Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide. Proc Natl Acad Sci USA 2008;105:488-493.